GLP-1R as a target for the treatment of diabetic retinopathy: Friend or foe?

Diabetes

Volumn 66, Issue 6, 2017, Pages 1453-1460

  Simó, Rafael ^a,b   Hernández, Cristina ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SEMAGLUTIDE; GLP1R PROTEIN, HUMAN; GLUCAGON LIKE PEPTIDE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL ASSESSMENT; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RETINA BLOOD VESSEL OCCLUSION; REVIEW; AGONISTS; ANIMAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; MOLECULARLY TARGETED THERAPY; MORTALITY; MYOCARDIAL INFARCTION; STROKE; TREATMENT OUTCOME;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MOLECULAR TARGETED THERAPY; MYOCARDIAL INFARCTION; STROKE; TREATMENT OUTCOME;

EID: 85019559864     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db16-1364     Document Type: Review

References (56)

1. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med 2012; 366:1227-1239
2. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010;376:124-136
3. Yau JW, Rogers SL, Kawasaki R, et al.; Meta-Analysis for Eye Disease (METAEYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556-564
4. Heintz E, Wiréhn AB, Peebo BB, Rosenqvist U, Levin LA. Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden. Diabetologia 2010;53:2147-2154
5. International Diabetes Federation. IDF Diabetes Atlas, 7th edition [Internet], 2015. Available from http://diabetesatlas.org. Accessed 15 January 2017
6. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-322
7. Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375: 1834-1844
8. Simó R, Hernández C. Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence. Prog Retin Eye Res 2015;48:160-180
9. Stitt AW, Curtis TM, Chen M, et al. The progress in understanding and treatment of diabetic retinopathy. Prog Retin Eye Res 2016;51:156-186
10. The Diabetes Control and Complications Trial Research Group. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998;116:874-886
11. Funatsu H, Yamashita H, Ohashi Y, Ishigaki T. Effect of rapid glycemic control on progression of diabetic retinopathy. Jpn J Ophthalmol 1992;36:356-367
12. Shurter A, Genter P, Ouyang D, Ipp E. Euglycemic progression: worsening of diabetic retinopathy in poorly controlled type 2 diabetes in minorities. Diabetes Res Clin Pract 2013;100:362-367
13. Henricsson M, Nilsson A, Janzon L, Groop L. The effect of glycaemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus. Diabet Med 1997;14:123-131
14. Roysarkar TK, Gupta A, Dash RJ, Dogra MR. Effect of insulin therapy on progression of retinopathy in noninsulin-dependent diabetes mellitus. Am J Ophthalmol 1993;115:569-574
15. Gorman DM, le Roux CW, Docherty NG. The effect of bariatric surgery on diabetic retinopathy: good, bad, or both? Diabetes Metab J 2016;40:354-364
16. Casson RJ, Wood JPM, Osborne NN. Hypoglycaemia exacerbates ischaemic retinal injury in rats. Br J Ophthalmol 2004;88:816-820
17. Simó R, Hernández C; European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. Br J Ophthalmol 2012;96:1285-1290
18. Abcouwer SF, Gardner TW. Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment. Ann N Y Acad Sci 2014;1311:174-190
19. Simó R, Hernández C; European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab 2014;25:23-33
20. Hölscher C. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS Drugs 2012;26:871-882
21. Yarchoan M, Arnold SE. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes 2014;63:2253-2261
22. Hernández C, Bogdanov P, Corraliza L, et al. Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. Diabetes 2016;65:172-187
23. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 2002;302:881-888
24. Pulido JE, Pulido JS, Erie JC, et al. A role for excitatory amino acids in diabetic eye disease. Exp Diabetes Res 2007;2007:36150
25. Zhang Y, Wang Q, Zhang J, Lei X, Xu G-T, Ye W. Protection of exendin-4 analogue in early experimental diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2009;247:699-706
26. Zhang Y, Zhang J, Wang Q, et al. Intravitreal injection of exendin-4 analogue protects retinal cells in early diabetic rats. Invest Ophthalmol Vis Sci 2011;52:278-285
27. Fan Y, Liu K, Wang Q, Ruan Y, Ye W, Zhang Y. Exendin-4 alleviates retinal vascular leakage by protecting the blood-retinal barrier and reducing retinal vascular permeability in diabetic Goto-Kakizaki rats. Exp Eye Res 2014;127:104-116
28. Fan Y, Liu K, Wang Q, Ruan Y, Zhang Y, Ye W. Exendin-4 protects retinal cells from early diabetes in Goto-Kakizaki rats by increasing the Bcl-2/Bax and Bcl-xL/Bax ratios and reducing reactive gliosis. Mol Vis 2014;20:1557-1568
29. Fu Z, Kuang HY, Hao M, Gao XY, Liu Y, Shao N. Protection of exenatide for retinal ganglion cells with different glucose concentrations. Peptides 2012;37: 25-31
30. Zeng Y, Yang K, Wang F, et al. The glucagon like peptide 1 analogue, exendin- 4, attenuates oxidative stress-induced retinal cell death in early diabetic rats through promoting Sirt1 and Sirt3 expression. Exp Eye Res 2016;151:203-211
31. Tomas E, Stanojevic V, Habener JF. GLP-1-derived nonapeptide GLP-1(28- 36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes. Regul Pept 2011;167:177-184
32. Sharma R, McDonald TS, Eng H, et al. In vitro metabolism of the glucagon-like peptide-1 (GLP-1)-derived metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in mouse and human hepatocytes. Drug Metab Dispos 2013;41:2148-2157
33. Giacco F, Du X, Carratú A, et al. GLP-1 cleavage product reverses persistent ROS generation after transient hyperglycemia by disrupting an ROS-generating feedback loop. Diabetes 2015;64:3273-3284
34. Wang D, Luo P, Wang Y, et al. Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism. Diabetes 2013;62:1697-1708
35. Simó R, Guerci B, Schernthaner G, et al. Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovasc Diabetol 2015;14:116
36. Kang YM, Jung CH. Cardiovascular effects of glucagon-like peptide-1 receptor agonists. Endocrinol Metab (Seoul) 2016;31:258-274
37. Xiao-Yun X, Zhao-Hui M, Ke C, Hong-Hui H, Yan-Hong X. Glucagon-like peptide-1 improves proliferation and differentiation of endothelial progenitor cells via upregulating VEGF generation. Med Sci Monit 2011;17:BR35-BR41
38. Kang HM, Kang Y, Chun HJ, Jeong JW, Park C. Evaluation of the in vitro and in vivo angiogenic effects of exendin-4. Biochem Biophys Res Commun 2013;434: 150-154
39. Aronis KN, Chamberland JP, Mantzoros CS. GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways. Metabolism 2013;62:1279-1286
40. Kang HM, Sohn I, Jung J, Jeong JW, Park C. Exendin-4 protects hindlimb ischemic injury by inducing angiogenesis. Biochem Biophys Res Commun 2015;465: 758-763
41. Sheu JJ, Chang MW, Wallace CG, et al. Exendin-4 protected against critical limb ischemia in obese mice. Am J Transl Res 2015;7:445-459
42. Sun Z, Tong G, Kim TH, et al. PEGylated exendin-4, a modified GLP-1 analog exhibits more potent cardioprotection than its unmodified parent molecule on a dose to dose basis in a murine model of myocardial infarction. Theranostics 2015;5:240-250
43. Du J, Zhang L, Wang Z, et al. Exendin-4 induces myocardial protection through MKK3 and Akt-1 in infarcted hearts. Am J Physiol Cell Physiol 2016;310:C270-C283
44. Puddu A, Sanguineti R, Montecucco F, Viviani GL. Retinal pigment epithelial cells express a functional receptor for glucagon-like peptide-1 (GLP-1). Mediators Inflamm 2013;2013:975032
45. U.S. Food and Drug Administration. Guidance for Industry: diabetes mellitus- evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [Internet], 2008. Available from www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidance/ucm071627.pdf. Accessed 2 July 2016
46. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326
47. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369: 1327-1335
48. Green JB, Bethel MA, Armstrong PW, et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373: 232-242
49. Pfeffer MA, Claggett B, Diaz R, et al.; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373: 2247-2257
50. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128
51. Garber A, Henry R, Ratner R, et al.; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-481
52. Pettitt DJ, Okada Wollitzer A, Jovanovic L, He G, Ipp E. Decreasing the risk of diabetic retinopathy in a study of case management: the California Medi-Cal Type 2 Diabetes Study. Diabetes Care 2005;28:2819-2822
53. Gonçalves A, Leal E, Paiva A, et al. Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model. Diabetes Obes Metab 2012;14:454-463
54. Maeda S, Yamagishi S, Matsui T, et al. Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats. Ophthalmic Res 2013;50:221-226
55. Gonçalves A, Marques C, Leal E, et al. Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats. Biochim Biophys Acta 2014;1842:1454-1463
56. Lee CS, Kim YG, Cho HJ, et al. Dipeptidyl peptidase-4 inhibitor increases vascular leakage in retina through VE-cadherin phosphorylation. Sci Rep 2016;6: 29393